Piper Jaffray analyst, Christopher Raymond, reiterated his Overweight rating on shares of Amgen (NASDAQ: AMGN) based on neurologist feedback on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE